Get Started in Minutes
How Perjeta Copay Assistance Works
1 – Check Your Coverage/Benefits Verification
Our team of expert billers finds the best avenues of coverage that minimize out-of-pocket costs.
2 – Transfer Prescription to AmeriPharma
We process your prescription by working with your previous pharmacy or prescriber, making the transition quick and easy.
3 – Prior Authorization
Our team of specialists obtains approval from your insurance companies within 24 to 72 hours.
4 – Copay Assistance & Financial Aid
We secure financial aid and decrease copays, out-of-pocket expenses, and high deductibles. To date, AmeriPharma Specialty Care has secured $55 million in financial assistance for our patients.
5 – Nursing Care Coordination
AmeriPharma puts your schedule and home environment first when scheduling and coordinating one of our specialized nurses for your in-home infusions.
6 – Delivery Coordination
Medications are always delivered in strict compliance with the specific requirements for immune globulin shipping. Next-day and overnight cold-chain deliveries are coordinated around your schedule.
What Is Perjeta?
Perjeta is a drug used alongside other medications to treat HER2-positive breast cancer. Patients will receive this medication in combination with Herceptin (trastuzumab) and chemotherapy.
Perjeta is approved for use in the following cancer types:
- HER2-positive metastatic breast cancer in those who have not received prior HER2 therapy or chemotherapy
- As the first part of a treatment plan for patients with HER2-positive breast cancer in the early stages, in an inflammatory state, or a locally advanced stage
- As an additional therapy in patients with HER2-positive breast cancer in the early stages, which demonstrates a high risk of recurrence
How Does Perjeta Work?
Perjeta works by interfering with the cancer cell’s ability to replicate and spread. HER2 stands for human epidermal growth factor receptor 2, and its job is to aid in cell replication. These receptors are part of both healthy and cancerous cells; however, HER2-positive breast cancer cells have more of these receptors. The additional receptors make the cancer cells replicate too quickly, resulting in tumors.
Perjeta is given alongside Herceptin to target cells with too many HER2 receptors. It is believed to block the signals from the HER2 receptors, thereby interfering with the replication process. Unfortunately, because healthy cells also have HER2 receptors, they may also be affected by Perjeta.
Copay and Financial Assistance
AmeriPharma Specialty Care alleviates financial burdens for patients and their families
Advanced software locates funding sources to match you with top-dollar foundation programs
One of our copay assistance specialists will assist with the application process
Automatic updates will be sent to you and your physician on the status of the funding
Perjeta Side Effects
Perjeta has some common side effects, including nausea, vomiting, diarrhea, hair loss, tiredness, and numbness/tingling in the feet. These side effects are usually mild and short-lived.
More severe side effects do sometimes happen with Perjeta. They may include:
- Severe allergic reactions such as a rash, hives, paleness, redness, itching, wheezing, or trouble breathing
- Infusion-related reactions consisting of flu-like symptoms, including fever, cough, headache, sore throat, and chills
- Heart problems, including swelling of the limbs, rapid heart rate, dizziness, shortness of breath, or weight gain of more than five pounds in 24 hours
Patients who experience any of these side effects should report them to their healthcare provider and seek immediate medical attention if symptoms become life-threatening. Perjeta is not approved for use during pregnancy as it may cause congenital disabilities or death to the unborn.
Perjeta Dosage Information
Perjeta is administered as an intravenous (IV) infusion directly into a vein by a medical professional. Depending on the indication, Parjeta may be given by itself or at the same time as other chemotherapy medications.
The first dose is 840 mg, given over 60 minutes via IV infusion. After the first session, patients receive another 420 mg every 3 weeks through 30- to 60-minute infusion sessions. Patients should be monitored for 30 to 60 minutes after each infusion to watch for allergic reactions and side effects.
Treatments may take place every 3 weeks for up to one year. Doctors may discontinue treatment earlier if the drug is no longer effective or if side effects make it too dangerous to continue. Patients who miss an infusion session should contact their doctor for instructions.